Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Amazon was struggling before mixed second-quarter results, but it has several attractive growth opportunities. Mounting ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

The S&P 500, the Dow Jones, and the NASDAQ all moved between 0.8% and 1% lower by mid-afternoon. Palantir (PLTR) stock ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future medicines to market.

U.S. pharmaceutical imports surged in March, exceeding $50 billion, as drugmakers stockpiled inventory in anticipation of ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

The stock's high price tag could be a problem for investors looking for a big return. Summit Therapeutics (NASDAQ: SMMT) has ...